BioAtla and GATC Health announced a $40 million special purpose vehicle (SPV) to advance ozuriftamab vedotin (Oz‑V), a CAB‑ROR2 antibody‑drug conjugate, into a registrational Phase 3 trial for second‑line and later oropharyngeal squamous cell carcinoma (OPSCC). The financing transaction aims to underwrite the registrational program and accelerate enrollment. The agreement signals investor support for targeted ADC strategies in head and neck cancers.